Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $5.1200 (2.4%) ($4.8700 - $5.1600) on Mon. Dec. 10, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.76% (three month average) | RSI | 43 | Latest Price | $5.1200(2.4%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.4% a day on average for past five trading days. | Market Behavior | Rotation from value to growth for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) EEM(7%) FXI(7%) KWEB(7%) MCHI(7%) BNDX(6%) | Factors Impacting TGTX price | TGTX will decline at least -3.38% in a week (0% probabilities). USO(-6%) UNG(-6%) GDX(-6%) XOP(-5%) UUP(-4%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.38% (StdDev 6.76%) | Hourly BBV | 0 () | Intraday Trend | 2.4% | | | |
|
5 Day Moving Average | $5.08(0.79%) | 10 Day Moving Average | $5.05(1.39%) | 20 Day Moving Average | $5.12(0%) | To recent high | -57% | To recent low | 2.4% | Market Cap | $648m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |